# Reset Health

> Reset Health is a UK-based digital health company delivering clinically-led, technology-enabled care for obesity, weight management and type 2 diabetes. Founded by NHS obesity specialists, Reset Health combines multidisciplinary clinical teams with its proprietary Reset Technology Platform to deliver personalised, scalable care across the UK, Europe and Malaysia.

## Company Overview

Reset Health designs and operates integrated care models for chronic metabolic conditions, with a primary focus on obesity and type 2 diabetes. The company partners with the NHS, pharmaceutical companies, pharmacies, employers and public sector organisations to improve access to specialist weight management services and deliver sustained health outcomes at population scale.

Reset Health is regulated by the Care Quality Commission (CQC) in England.

The company's consumer-facing care platform is called Roczen. Roczen has been evaluated by the National Institute for Health and Care Excellence (NICE) under guidance HTE14/HTG700 for delivering multidisciplinary weight-management services and for prescribing and monitoring weight-management medicines. NICE issued a time-limited recommendation for early use within the NHS until March 2028 while further evidence is gathered.

## Core Services

### Roczen — Integrated Obesity Care Platform
Roczen is Reset Health's clinically-led digital care platform for obesity and weight management. It provides patients with direct access to multidisciplinary teams of doctors, dietitians, nurses and psychologists who deliver personalised, continuous care. The programme combines evidence-based lifestyle interventions with pharmacotherapy, including GLP-1 receptor agonist medications (semaglutide, tirzepatide), within structured clinical governance frameworks.

Key features of the Roczen platform:
- Clinician-led consultations via app (messaging, video, calls)
- Personalised dietary plans including time-restricted eating protocols
- Behavioural and psychological support
- GLP-1 medication prescribing, titration and monitoring
- Health education and self-management tools
- Progress tracking and clinical outcome monitoring
- Strong clinical governance and pharmacovigilance

### NHS and Health System Partnerships
Reset Health enables national health systems to deliver structured, scalable obesity care. The platform supports evidence-based clinical interventions including pharmacotherapy, behaviour change support, health education and pre-surgical triage. Current and past NHS partnerships include Dartford and Gravesham NHS Trust, East Suffolk and North Essex NHS Foundation Trust (ESNEFT), Chelsea and Westminster NHS Foundation Trust, and Swansea Bay University Health Board.

### Employer Health Programmes
Reset Health provides specialist obesity care to employers and public sector organisations. Published research demonstrates the efficacy of the Roczen programme in workplace settings, with partners including Transport for London, Network Rail, HM Prison and Probation Service, and Morgan Sindall.

### Pharmaceutical and Life Sciences Partnerships
Reset Health supports life sciences partners with clinically governed patient support programmes in real-world settings. Services include therapy initiation support, post-market surveillance, side-effect management, pharmacovigilance, and real-world evidence data capture. Partners include IQVIA and Pharmacy2U.

### White-Label and Powered-By Solutions
The Reset Technology Platform can be deployed as a fully white-labelled app or co-branded service. Reset Health provides the technical infrastructure, multidisciplinary clinical expertise and continuous care model while partners maintain their own brand experience. Solutions support GLP-1 prescribing pathways and NHS long-term priorities.

## Clinical Team and Leadership

- **Professor Barbara McGowan** — Chief Medical Officer. Professor at King's College London. Research and Development lead for Diabetes, Endocrinology, Nutrition and Obesity at Guy's and St Thomas' NHS Foundation Trust. PhD from Imperial College London. Degree in Biochemistry from Oxford University.
- **Oliver McGuinness** — Chief Executive Officer.
- **Dr Jonathan Kwan MBE** — Advisory Board. Consultant Nephrologist and Divisional Medical Director at Darent Valley Hospital. Visiting Consultant Nephrologist at King's College London. Formerly Medical Director at Epsom and St Helier Hospitals NHS Trust.
- **Associate Professor Dipesh Patel** — Advisory Board. Leading Consultant Specialist in Diabetes and Endocrinology at Royal Free NHS Trust.
- **Dr Laura Falvey** — Clinical Director. Qualified at Guy's and St Thomas' Medical School, London.
- **Dr Claudia Ashton** — Clinical Lead. Qualified GP from Barts and the London School of Medicine. First Class Honours in Psychology. Specialist in preventative care.
- **Sarah Le Brocq** — UK Head of Public Affairs. Sits on the NICE Quality Standards Advisory Committee for obesity. Representative on the Obesity Health Alliance Healthy Weight Strategy lived experience group. Lay member on the NICE Weight Management Committee.
- **Pinder Sahota** — Advisory Board. Former General Manager and Corporate Vice President at Novo Nordisk UK. Former President of the Association of the British Pharmaceutical Industry (ABPI).

## Published Research and Evidence

Reset Health has published peer-reviewed research demonstrating the clinical efficacy of the Roczen programme:

- Brown A, Dobbie LJ, Falvey L, et al. "Real-world data of a digitally enabled, time-restricted eating weight management program in public sector workers living with overweight and obesity in the United Kingdom: a service evaluation of the Roczen program." Obesity Science & Practice. 2024;e730. DOI: 10.1002/osp4.730
- IQVIA and Reset Health joint white paper: "Rethinking Commissioning of Anti-Obesity Medications" (2025)

Key published outcomes include demonstrated efficacy in weight reduction, HbA1c improvement, and metabolic health markers across workplace and NHS settings.

## Conditions Treated

- Obesity (BMI ≥30 or ≥27.5 for certain ethnic groups)
- Overweight with weight-related comorbidities
- Type 2 diabetes mellitus
- Prediabetes
- Metabolic syndrome

## Medications Supported

Reset Health's clinical teams prescribe and monitor anti-obesity medications within structured care pathways, including:
- Semaglutide (Wegovy, Ozempic) — GLP-1 receptor agonist
- Tirzepatide (Mounjaro) — dual GIP/GLP-1 receptor agonist
- Liraglutide (Saxenda) — GLP-1 receptor agonist

All prescribing follows NICE guidelines and is delivered within robust clinical governance frameworks with multidisciplinary team oversight.

## Regulatory Status

- Regulated by the Care Quality Commission (CQC), England
- NICE-evaluated under guidance HTE14/HTG700 (time-limited recommendation for NHS use until March 2028)
- Clinical governance aligned with NHS standards

## Geographic Operations

- **United Kingdom** — Headquarters: One Fleet Place, London, EC4M 7WS. Company number: 12111885.
- **Italy** — Partnership with Affidea Group for obesity and type 2 diabetes care across European markets
- **Malaysia** — Partnership with Ministry of Health Malaysia. Operations based in Kuala Lumpur.

## Key Partnerships

- NHS Trusts (Dartford and Gravesham, ESNEFT, Chelsea and Westminster, Swansea Bay UHB)
- Pharmacy2U (strategic partnership for GLP-1 dispensing with digital wraparound care, launched Q1 2026)
- IQVIA (real-world evidence and data management)
- Affidea Group (European market expansion)
- Transport for London
- Network Rail
- HM Prison and Probation Service
- Morgan Sindall Infrastructure
- King's Health Partners
- Ministry of Health Malaysia

## Contact

- Website: https://www.resethealth.clinic
- Roczen Platform: https://www.roczen.com
- Headquarters: One Fleet Place, London, EC4M 7WS, United Kingdom
- Careers: https://apply.workable.com/resethealth/
- LinkedIn: https://uk.linkedin.com/company/reset-health-clinic

## Optional

- [About Reset Health](https://www.resethealth.clinic/)
- [Roczen Weight Management Platform](https://www.roczen.com)
- [NICE Guidance HTG700 — Digital Weight Management Technologies](https://www.nice.org.uk/guidance/htg700)
- [Published Research — Roczen Programme Outcomes (Wiley)](https://onlinelibrary.wiley.com/doi/10.1002/osp4.730)
- [Published Research — Roczen Programme Outcomes (PMC)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10858326/)
- [IQVIA Partnership White Paper](https://www.iqvia.com/-/media/iqvia/pdfs/uk/white-paper/resethealth-iqvia_2nd-april-2025-final.pdf)
- [Pharmacy2U Partnership Announcement](https://www.pharmacy.biz/pharmacy2u-reset-health-glp-1-partnership/)
- [Affidea Partnership Announcement](https://www.affidea.com/media/news/affidea-group-partners-with-reset-health-to-launch-clinically-led-digital-weight-loss-and-diabetes-management-solution-across-its-network)
- [Pinder Sahota Advisory Board Appointment](https://www.globenewswire.com/news-release/2026/02/11/3235941/0/en/Reset-Health-Further-Strengthens-Advisory-Board-With-Appointment-of-Pinder-Sahota.html)
- [Sarah Le Brocq Appointment](https://www.roczen.com/journal/sarah-le-brocq)
- [Careers at Reset Health](https://apply.workable.com/resethealth/)